{"id":214294,"date":"2020-02-23T07:42:48","date_gmt":"2020-02-23T12:42:48","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=214294"},"modified":"2020-02-23T07:42:48","modified_gmt":"2020-02-23T12:42:48","slug":"cuba-and-thailand-joint-venture-to-manufacture-cancer-drugs","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/cuba\/cuba-and-thailand-joint-venture-to-manufacture-cancer-drugs\/","title":{"rendered":"Cuba and Thailand joint venture to manufacture cancer drugs"},"content":{"rendered":"

A Cuba and Thailand joint venture will soon start manufacturing <\/span>cancer<\/span><\/a> drugs, the Cuban media reported this Friday.<\/span><\/p>\n

The enterprise is formed by the Thai pharmaceutical company Siam Bioscience (SBS) and the Cuban medicine industry and its operations will be initiated in the Association of South East Asian Nations (ASEAN), <\/span>according to <\/span><\/a>the official newspaper <\/span>Granma<\/span><\/i>, which quoted a tweet from Eduardo Ojito, director of Cuba\u2019s Center for Molecular Immunology (CIM).<\/span><\/p>\n

The publication affirms that the company emerged in 2017 to produce \u201cworld-class drugs for complicated diseases,\u201d whereby the Thai SBS and the Cuban CIM agreed to jointly develop monoclonal antibodies to treat cancer and autoimmune diseases.<\/span><\/p>\n

Songpon Deechongkit, general director of Siam Bioscience Group, to which SBS belongs, <\/span>assured<\/span><\/a> the <\/span>Bangkok Post<\/span><\/i> that by 2022 the enterprise plans to produce and sell three new drugs for cancer, kidney failure and autoimmune diseases, both in Thailand and abroad.<\/span><\/p>\n

For his part, Agust\u00edn Lage D\u00e1vila, general director of CIM, told the publication itself that the agreement will help SBS produce other medicines when its patent expires, through the skills created in it.<\/span><\/p>\n

Dos nuevos medicamentos para el c\u00e1ncer dan buenos resultados<\/a><\/p><\/blockquote>\n